Barclays analyst, Geoff Meacham, reiterated his Overweight rating on shares of Moderna (NASDAQ: MRNA) and raised his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE